Product Images Tizanidine Hydrochloride

This is a medication called Tizanidine Hydrochloride, contained in capsules of 2.28mg, equivalent to 2mg of Tizanidine base. It is recommended to store at room temperature, between 15°C-30°C. The medication should be kept out of reach of children and dispensed in containers with child-resistant closure. Zaralet is a registered trademark of Acorda Therapeutics and the medication is manufactured by Cadila Pharmaceutical Ltd. for Nivagen Pharmaceutical, Inc. For more information, it is recommended to refer to the insert.*

This is a description of Tizanidine Hydrochloride Capsules. Each capsule contains 4.58 mg of tizanidine hydrochloride, which is equivalent to 4 mg of tizanidine base. It is a prescription medication that should be stored at room temperature between 15° to 30° Celsius. It is recommended to read the package insert for dosing information. The medication should be dispensed in containers with child-resistant closures and kept out of reach of children. The brand name for this medication is Zanaflex® which is a registered trademark of Acorda Therapeutics Inc. The medication is manufactured for Nivagen Pharmaceuticals, Inc. The phone number for the manufacturer is 1-877-877-0687. The manufacturer of the medication is Cadta Pharmaceuticals Ltd. located in Gujarat, India. The expiration date for this medication was March 2019.*

This is a description of a medication called Tizanidine Hydrochloride Capsules with NDC (National Drug Code) 75834-209-15. The medication is available in a container with 150 capsules. Each capsule contains .87 mg of Tizanidine Hydrochloride, which is equal to 6 mg of Zanaflex base. The storage temperature is recommended at 25°C (77°F) with permitted temperature excursions between 15°C to 30°C (53°F to 86°F). The medication should be kept out of reach of children. The package insert should be referred to for more information. The medication is manufactured by Cadila Pharmaceuticals Ltd in India and is distributed by Nivagen in Sacramento, USA. The medication is a registered trademark of Acorda Therapeutics. The last issuance date of this information is March 2019.*